Share Buyback

EKF Diagnostics Holdings PLC

31 March 2026

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Share Buyback

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 100,000 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 23.6 pence per share. The Ordinary Shares purchased will be held in treasury. Harwood Capital Management has not sold any ordinary shares to the Company as part of yesterday's purchases.

Aggregated information

Date of purchase	30 March 2026
Number of Ordinary Shares purchased	100,000
Highest price paid per Ordinary Share	23.6p
Lowest price paid per Ordinary Share	23.6p
Volume weighted average price paid	23.6p

 Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:

Number of Ordinary Shares purchased	Transaction price (GBp)	Time of transaction	Trading venue
50,000	23.6p	09:40:36	AIMX
50,000	23.6p	10:23:51	AIMX

Total voting rights

Following the purchase, the Company's total issued share capital will consist of 431,963,112 Ordinary Shares, of which 965,000 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 430,998,112. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). 

The person responsible for arranging the release of this Announcement
on behalf of the Company is Julian Baines, Executive Chair.

EKF Diagnostics Holdings plc		www.ekfdiagnostics.com
Julian Baines, Executive Chair		via Walbrook PR
Gavin Jones, Chief Executive Officer
Singer Capital Markets (Nominated Adviser & Broker)			Tel: [phone]
Phil Davies / Patrick Weaver
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus / Alice Woodings	Mob: [phone]

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

●	Point-of-Care analysers in the key areas of Hematology and Diabetes
●	Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

END